Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (2434)	4/19/1999 1:14:00 PM
From: quidditch	Read Replies (1) \| Respond to of 10280

Any one have any insight as to how SEPR's improved form of Prozac profile compares with the other SSR's now (or soon to be) on the market, in terms of side effects, dosing (frequency/mg) and cost? Regards. Liacos_samui

To: BMcV who wrote (2434)	4/19/1999 2:13:00 PM
From: Don Miller	Respond to of 10280

Ya, We added some day traders worth about 1-2 million shares per day. The flies have found our meat and potatoes!

To: BMcV who wrote (2434)	4/19/1999 3:17:00 PM
From: David Howe	Read Replies (2) \| Respond to of 10280

The reason I'm in this stock is definitely because they may have X amount of earnings in year Y. No other reason. Clearly the stock market has a mind of it's own at times. The value of SEPR today is approximately the same as it was two weeks ago, IMO. The price per share is much lower. I'm looking a few years out. Buying and holding. I don't trade options although IMO calls and leaps are at attractive prices right now. The 4% drop in Prozac sales is so insignificant that the earnings model is barely worth modifying. This is a somewhat off base comparison, but would you care if you were given $2.7 billion instead of $2.8 billion? Dave